133 related articles for article (PubMed ID: 29212171)
1. Clinical outcomes and prognostic factors of stereotactic body radiation therapy for intrahepatic cholangiocarcinoma.
Shen ZT; Zhou H; Li AM; Li B; Shen JS; Zhu XX
Oncotarget; 2017 Nov; 8(55):93541-93550. PubMed ID: 29212171
[TBL] [Abstract][Full Text] [Related]
2. Actual over 3-year survival after stereotactic body radiation therapy in patients with unresectable intrahepatic cholangiocarcinoma.
Zhang XX; Ma HB; Li TH; Huang B; Jia NY; Meng Y
Clin Transl Oncol; 2023 Mar; 25(3):731-738. PubMed ID: 36401766
[TBL] [Abstract][Full Text] [Related]
3. Stereotactic Body Radiotherapy (SBRT) for Spinal Metastases: Who Will Benefit the Most from SBRT?
Park HJ; Kim HJ; Won JH; Lee SC; Chang AR
Technol Cancer Res Treat; 2015 Apr; 14(2):159-67. PubMed ID: 24502552
[TBL] [Abstract][Full Text] [Related]
4. Stereotactic Body Radiotherapy (SBRT) for Intrahepatic and Hilar Cholangiocarcinoma.
Mahadevan A; Dagoglu N; Mancias J; Raven K; Khwaja K; Tseng JF; Ng K; Enzinger P; Miksad R; Bullock A; Evenson A
J Cancer; 2015; 6(11):1099-104. PubMed ID: 26516357
[TBL] [Abstract][Full Text] [Related]
5. Stereotactic radiotherapy in intrahepatic cholangiocarcinoma: A systematic review.
Bisello S; Camilletti AC; Bertini F; Buwenge M; Arcelli A; Macchia G; Deodato F; Cilla S; Mattiucci G; Autorino R; Brandi G; Strigari L; Cammelli S; Morganti AG
Mol Clin Oncol; 2021 Aug; 15(2):152. PubMed ID: 34141431
[TBL] [Abstract][Full Text] [Related]
6. Stereotactic body radiation therapy in recurrent hepatocellular carcinoma.
Huang WY; Jen YM; Lee MS; Chang LP; Chen CM; Ko KH; Lin KT; Lin JC; Chao HL; Lin CS; Su YF; Fan CY; Chang YW
Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):355-61. PubMed ID: 22342300
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
Tse RV; Hawkins M; Lockwood G; Kim JJ; Cummings B; Knox J; Sherman M; Dawson LA
J Clin Oncol; 2008 Feb; 26(4):657-64. PubMed ID: 18172187
[TBL] [Abstract][Full Text] [Related]
8. Modified response evaluation criteria in solid tumors and European Association for The Study of the Liver criteria using delayed-phase imaging at an early time point predict survival in patients with unresectable intrahepatic cholangiocarcinoma following yttrium-90 radioembolization.
Camacho JC; Kokabi N; Xing M; Prajapati HJ; El-Rayes B; Kim HS
J Vasc Interv Radiol; 2014 Feb; 25(2):256-65. PubMed ID: 24461131
[TBL] [Abstract][Full Text] [Related]
9. Multicenter results of stereotactic body radiotherapy (SBRT) for non-resectable primary liver tumors.
Ibarra RA; Rojas D; Snyder L; Yao M; Fabien J; Milano M; Katz A; Goodman K; Stephans K; El-Gazzaz G; Aucejo F; Miller C; Fung J; Lo S; Machtay M; Sanabria JR
Acta Oncol; 2012 May; 51(5):575-83. PubMed ID: 22263926
[TBL] [Abstract][Full Text] [Related]
10. Stereotactic body radiotherapy (SBRT) for locally advanced extrahepatic and intrahepatic cholangiocarcinoma.
Sandler KA; Veruttipong D; Agopian VG; Finn RS; Hong JC; Kaldas FM; Sadeghi S; Busuttil RW; Lee P
Adv Radiat Oncol; 2016; 1(4):237-243. PubMed ID: 28740893
[TBL] [Abstract][Full Text] [Related]
11. Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma >5 cm.
Su TS; Lu HZ; Cheng T; Zhou Y; Huang Y; Gao YC; Tang MY; Jiang HY; Lian ZP; Hou EC; Liang P
BMC Cancer; 2016 Nov; 16(1):834. PubMed ID: 27809890
[TBL] [Abstract][Full Text] [Related]
12. Vertebral compression fractures after stereotactic body radiation therapy: a large, multi-institutional, multinational evaluation.
Jawad MS; Fahim DK; Gerszten PC; Flickinger JC; Sahgal A; Grills IS; Sheehan J; Kersh R; Shin J; Oh K; Mantel F; Guckenberger M;
J Neurosurg Spine; 2016 Jun; 24(6):928-36. PubMed ID: 26895526
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Factors for Elderly Patients Treated With Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma.
Sutera PA; Bernard ME; Wang H; Heron DE
Front Oncol; 2018; 8():282. PubMed ID: 30101127
[No Abstract] [Full Text] [Related]
14. Stereotactic body radiotherapy for unresectable cholangiocarcinoma.
Kopek N; Holt MI; Hansen AT; Høyer M
Radiother Oncol; 2010 Jan; 94(1):47-52. PubMed ID: 19963295
[TBL] [Abstract][Full Text] [Related]
15. Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer: A Retrospective, Single-Center Study of 55 Patients.
Bhandari RP; Stanford JD; Packianathan S; Duggar WN; Kanakamedala MR; Zhang X; Giri SP; Kumar PP; Harrell LM; Mangana SH; Yang C; Vijayakumar S
Oncology; 2016; 91(4):194-204. PubMed ID: 27427761
[TBL] [Abstract][Full Text] [Related]
16. Medically inoperable peripheral lung cancer treated with stereotactic body radiation therapy.
Kelley KD; Benninghoff DL; Stein JS; Li JZ; Byrnes RT; Potters L; Knisely JP; Zinkin HD
Radiat Oncol; 2015 May; 10():120. PubMed ID: 26018408
[TBL] [Abstract][Full Text] [Related]
17. Re-irradiation stereotactic body radiotherapy for spinal metastases: a multi-institutional outcome analysis.
Hashmi A; Guckenberger M; Kersh R; Gerszten PC; Mantel F; Grills IS; Flickinger JC; Shin JH; Fahim DK; Winey B; Oh K; John Cho BC; Létourneau D; Sheehan J; Sahgal A
J Neurosurg Spine; 2016 Nov; 25(5):646-653. PubMed ID: 27341054
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of stereotactic body radiotherapy for unresectable primary or recurrent cholangiocarcinoma.
Jung DH; Kim MS; Cho CK; Yoo HJ; Jang WI; Seo YS; Paik EK; Kim KB; Han CJ; Kim SB
Radiat Oncol J; 2014 Sep; 32(3):163-9. PubMed ID: 25324988
[TBL] [Abstract][Full Text] [Related]
19. Stereotactic Body Radiotherapy for Recurrent or Oligometastatic Uterine Cervix Cancer: A Cooperative Study of the Korean Radiation Oncology Group (KROG 14-11).
Park HJ; Chang AR; Seo Y; Cho CK; Jang WI; Kim MS; Choi C
Anticancer Res; 2015 Sep; 35(9):5103-10. PubMed ID: 26254414
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes and dosimetric considerations using stereotactic body radiotherapy for abdominopelvic tumors.
Barney BM; Olivier KR; Macdonald OK; Fong de Los Santos LE; Miller RC; Haddock MG
Am J Clin Oncol; 2012 Dec; 35(6):537-42. PubMed ID: 21659830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
